Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13373174 | 0.83 | TAAR1 (0.54) | ATMTAAR1SIGMAR1SMN1; SMN2NPC1 | |
| SCHEMBL7530984 | 0.78 | TMEM97 (0.61) | TAAR1SIGMAR1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL7285776 | 0.78 | TAAR1 (0.54) | ATMTAAR1SIGMAR1SMN1; SMN2NPC1 | |
| SCHEMBL56059 | 0.77 | ADH1B (0.61) | ATMTAAR1SIGMAR1SMN1; SMN2NPC1 | |
| SCHEMBL4553369 | 0.77 | NPC1 (0.52) | ATMTAAR1SIGMAR1SMN1; SMN2NPC1 | |
| SCHEMBL7736614 | 0.77 | ALDH1A1 (0.52) | ATMTAAR1SIGMAR1SMN1; SMN2NPC1 | |
| SCHEMBL7963483 | 0.77 | NPC1 (0.52) | ATMTAAR1SIGMAR1SMN1; SMN2NPC1 | |
| SCHEMBL28850288 | 0.77 | ALDH1A1 (0.54) | ATMTAAR1SIGMAR1SMN1; SMN2NPC1 | |
| SCHEMBL2117911 | 0.76 | ADH1B (0.60) | SIGMAR1SMN1; SMN2NPC1RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL9344083 | 0.76 | L3MBTL1 (0.52) | ATMTAAR1SIGMAR1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107973788-B | BBI608 derivative and preparation and application thereof | 沈阳药科大学 | 2021-07-09 | — | — | CN | disclosed |
| EP-2099442-A1 | METHOD OF USING HISTONE DEACETYLASE INHIBITORS AND MONITORING BIOMARKERS IN COMBINATION THERAPY | PHARMACYCLICS, INC. (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008082856-A1 | METHOD OF USING HISTONE DEACETYLASE INHIBITORS AND MONITORING BIOMARKERS IN COMBINATION THERAPY | PHARMACYCLICS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20050261164-A1 | Remedy for urinary frequency and urinary incontinence | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1532978-A1 | REMEDY FOR URINARY FREQUENCY AND URINARY INCONTINENCE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-25 | — | — | EP | disclosed |
| US-6248772-B1 | HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| US-6169107-B1 | USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS | SUMITOMO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-0937459-A2 | Pharmaceutical compositions for the treatment of ischemic brain damage | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1999-08-25 | — | — | EP | disclosed |
| EP-0622356-B1 | Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange | SUMITOMO PHARMA (JP) | 1998-07-01 | — | — | EP | disclosed |
| EP-0804434-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1997-11-05 | — | — | EP | disclosed |
| US-5508403-A | ENHANCES EFFECTS OF ANTITUMOR AGENTS | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1996-04-16 | — | — | US | disclosed |
| WO-1996004274-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1996-02-15 | — | — | WO | disclosed |
| EP-0353692-B1 | Drug effect-enhancing agent for antitumor drug | NISSAN CHEMICAL IND LTD (JP) | 1995-10-04 | — | — | EP | disclosed |
| EP-0655455-A1 | Novel phosporus containing pyridine derivatives | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1995-05-31 | — | — | EP | disclosed |
| EP-0622356-A1 | Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1994-11-02 | — | — | EP | disclosed |
| US-5304550-A | Synergistic | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1994-04-19 | — | — | US | disclosed |
| WO-1994007815-A2 | SMALL PEPTIDE ANAPHYLATOXIN RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 1994-04-14 | — | — | WO | disclosed |
| WO-1994007518-A1 | ANAPHYLATOXIN RECEPTOR LIGANDS CONTAINING LIPOPHILIC RESIDUES | ABBOTT LABORATORIES (US) | 1994-04-14 | — | — | WO | disclosed |
| US-5130303-A | Pyridine derivative administering | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1992-07-14 | — | — | US | disclosed |
| EP-0353692-A2 | Drug effect-enhancing agent for antitumor drug | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1990-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261164-A1 | Remedy for urinary frequency and urinary incontinence | SLC14A1, SLC26A4, SLC6A12 | ATM 4418/4885TAAR1 1307/4885SIGMAR1 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.